Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atara Biotherapeutics (ATRA)
NASDAQ:ATRA
Holding ATRA?
Track your performance easily
ATRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.50 - $39.50
Previous CloseN/A
Volume32.09K
Average Volume (3M)199.96K
Market Cap
$45.10M
Enterprise Value$81.44M
Total Cash (Recent Filing)$255.68M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 03, 2025EPS Estimate
-1.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.66
Shares Outstanding5,759,750
10 Day Avg. Volume425,158
30 Day Avg. Volume199,957
Standard Deviation0.26
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.75
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit-260.19
Enterprise Value/Ebitda-0.52
Forecast
1Y Price Target
$13.50Price Target Upside72.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Atara Biotherapeutics News
Ownership Overview
33.52% Insiders
7.38% Mutual Funds
20.40% Other Institutional Investors
35.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ATRA FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
Atara Biotherapeutics lowest stock price was $6.50 and its highest was $39.50 in the past 12 months.
What is Atara Biotherapeutics’s market cap?
Atara Biotherapeutics’s market cap is $45.10M.
When is Atara Biotherapeutics’s upcoming earnings report date?
Atara Biotherapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Atara Biotherapeutics’s earnings last quarter?
Atara Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$1.888 by -$1.042.
Is Atara Biotherapeutics overvalued?
According to Wall Street analysts Atara Biotherapeutics’s price is currently Undervalued.
Does Atara Biotherapeutics pay dividends?
Atara Biotherapeutics does not currently pay dividends.
What is Atara Biotherapeutics’s EPS estimate?
Atara Biotherapeutics’s EPS estimate is -1.86.
How many shares outstanding does Atara Biotherapeutics have?
Atara Biotherapeutics has 5,759,750 shares outstanding.
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Atara Biotherapeutics reported an EPS of -$2.93 in its last earnings report, missing expectations of -$1.888. Following the earnings report the stock price went up 22.194%.
Which hedge fund is a major shareholder of Atara Biotherapeutics?
Among the largest hedge funds holding Atara Biotherapeutics’s share is Woodline Partners LP. It holds Atara Biotherapeutics’s shares valued at 0.
---
Atara Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (72.41% Upside)
$13.50 (72.41% Upside)
Blogger Sentiment
Bullish
ATRA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $45.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-56.07%
12-Months-Change
Fundamentals
Return on Equity
1063.61%
Trailing 12-Months
Asset Growth
-24.41%
Trailing 12-Months
Company Description
Atara Biotherapeutics
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
---
ATRA Earnings Call
Q3 2023
0:00 / 0:00
---
ATRA Stock 12 Month Forecast
Average Price Target
$13.50
▲(72.41% Upside)
Technical Analysis
Allogene Therapeutics
―
Fate Therapeutics
―
Cellectis SA
―
Gritstone bio
―
Iovance Biotherapeutics
―
Vertex Pharmaceuticals
―
Best Analysts Covering ATRA
1 Year
1 Year Success Rate
20/40 ratings generated profit
1 Year Average Return
+8.50%
reiterated a buy rating 2 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.50% per trade.
---